ArticleInternational journal of biological sciences2022

Conjugate of ibrutinib with a TLR7 agonist suppresses melanoma progression and enhances antitumor immunity.

Sumei Ren et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.